Latest Insider Transactions at Johnson & Johnson (JNJ)
This section provides a real-time view of insider transactions for Johnson & Johnson (JNJ). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of JOHNSON & JOHNSON to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of JOHNSON & JOHNSON's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 12
2024
|
Joseph J Wolk Exec VP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,835
+13.64%
|
-
|
|
Feb 12
2024
|
William Hait EVP, Chief EI and Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,076
-9.63%
|
$639,932
$157.4 P/Share
|
|
Feb 12
2024
|
William Hait EVP, Chief EI and Med Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,932
+9.33%
|
-
|
|
Feb 12
2024
|
Vanessa Broadhurst EVP, Global Corp Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
2,136
-8.26%
|
$335,352
$157.4 P/Share
|
|
Feb 12
2024
|
Vanessa Broadhurst EVP, Global Corp Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
790
+2.96%
|
-
|
|
Feb 12
2024
|
Vanessa Broadhurst EVP, Global Corp Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
4,701
+15.78%
|
-
|
|
Feb 09
2024
|
Kathryn E Wengel EVP, Chief TO and Risk Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
27,333
-26.66%
|
$4,263,948
$156.76 P/Share
|
|
Feb 09
2024
|
Kathryn E Wengel EVP, Chief TO and Risk Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
35,638
+25.79%
|
$3,207,420
$90.44 P/Share
|
|
Feb 09
2024
|
Joaquin Duato CEO and Chairman of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
98,662
-22.46%
|
$15,391,272
$156.76 P/Share
|
|
Feb 09
2024
|
Joaquin Duato CEO and Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
130,969
+22.97%
|
$11,787,210
$90.44 P/Share
|
|
Feb 09
2024
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
SELL
Open market or private sale
|
Direct |
59,397
-29.58%
|
$9,265,932
$156.27 P/Share
|
|
Feb 09
2024
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
BUY
Exercise of conversion of derivative security
|
Direct |
59,397
+22.83%
|
$5,345,730
$90.44 P/Share
|
|
Feb 08
2024
|
William Hait EVP, Chief EI and Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,113
-3.23%
|
$173,628
$156.33 P/Share
|
|
Feb 08
2024
|
William Hait EVP, Chief EI and Med Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,059
+8.15%
|
-
|
|
Feb 08
2024
|
Timothy Schmid EVP, WW Chair, MedTech |
SELL
Payment of exercise price or tax liability
|
Direct |
1,001
-9.15%
|
$156,156
$156.33 P/Share
|
|
Feb 08
2024
|
Timothy Schmid EVP, WW Chair, MedTech |
BUY
Exercise of conversion of derivative security
|
Direct |
1,964
+15.22%
|
-
|
|
Feb 08
2024
|
James D. Swanson EVP, CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
554
-4.99%
|
$86,424
$156.33 P/Share
|
|
Feb 08
2024
|
James D. Swanson EVP, CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,868
+14.39%
|
-
|
|
Feb 08
2024
|
Elizabeth Forminard Executive VP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
363
-5.62%
|
$56,628
$156.33 P/Share
|
|
Feb 08
2024
|
Elizabeth Forminard Executive VP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
979
+13.16%
|
-
|
|
Feb 08
2024
|
Joseph J Wolk Exec VP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,047
-1.94%
|
$163,332
$156.33 P/Share
|
|
Feb 08
2024
|
Joseph J Wolk Exec VP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,686
+6.4%
|
-
|
|
Feb 08
2024
|
Kathryn E Wengel EVP, Chief TO and Risk Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,009
-1.49%
|
$157,404
$156.33 P/Share
|
|
Feb 08
2024
|
Kathryn E Wengel EVP, Chief TO and Risk Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,971
+2.82%
|
-
|
|
Feb 08
2024
|
Joaquin Duato CEO and Chairman of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
2,269
-0.73%
|
$353,964
$156.33 P/Share
|
|
Feb 08
2024
|
Joaquin Duato CEO and Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
5,225
+1.65%
|
-
|
|
Feb 08
2024
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
SELL
Payment of exercise price or tax liability
|
Direct |
1,913
-1.33%
|
$298,428
$156.33 P/Share
|
|
Feb 08
2024
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
BUY
Exercise of conversion of derivative security
|
Direct |
3,739
+2.54%
|
-
|
|
Feb 08
2024
|
Robert J Decker VP Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
215
-1.22%
|
$33,540
$156.33 P/Share
|
|
Feb 08
2024
|
Robert J Decker VP Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
655
+3.59%
|
-
|
|
Feb 08
2024
|
Vanessa Broadhurst EVP, Global Corp Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
703
-3.33%
|
$109,668
$156.33 P/Share
|
|
Feb 08
2024
|
Vanessa Broadhurst EVP, Global Corp Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
1,880
+8.19%
|
-
|
|
Feb 08
2024
|
Peter Fasolo Exec VP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
781
-0.75%
|
$121,836
$156.33 P/Share
|
|
Feb 08
2024
|
Peter Fasolo Exec VP, Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,135
+2.0%
|
-
|
|
Aug 23
2023
|
Joseph J Wolk Exec VP, CFO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
67
-0.13%
|
-
|
|
Aug 23
2023
|
Joaquin Duato CEO and Chairman of the Board |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,035
-3.49%
|
-
|
|
Aug 23
2023
|
Peter Fasolo Exec VP, Chief HR Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
232
-0.23%
|
-
|
|
Aug 23
2023
|
Ashley Mc Evoy EVP, WW Chair, MedTech |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,787
-5.08%
|
-
|
|
Aug 23
2023
|
William Hait EVP, Chief EI and Med Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
696
-0.79%
|
-
|
|
Jul 26
2023
|
William Hait EVP, Chief EI and Med Officer |
SELL
Open market or private sale
|
Direct |
14,698
-14.35%
|
$2,528,056
$172.0 P/Share
|
|
Jul 26
2023
|
William Hait EVP, Chief EI and Med Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,698
+12.55%
|
$1,322,820
$90.44 P/Share
|
|
Jul 25
2023
|
Peter Fasolo Exec VP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
20,000
-16.3%
|
$3,400,000
$170.32 P/Share
|
|
Jun 12
2023
|
Kathryn E Wengel EVP, Chief TO and Risk Officer |
SELL
Open market or private sale
|
Direct |
12,465
-15.9%
|
$1,994,400
$160.0 P/Share
|
|
May 24
2023
|
Joseph J Wolk Exec VP, CFO |
SELL
Bona fide gift
|
Direct |
55
-0.11%
|
-
|
|
Mar 06
2023
|
James D. Swanson EVP, CIO |
SELL
Open market or private sale
|
Direct |
1,061
-10.33%
|
$163,394
$154.66 P/Share
|
|
Feb 13
2023
|
Elizabeth Forminard Executive VP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
924
-14.42%
|
$149,688
$162.01 P/Share
|
|
Feb 13
2023
|
Elizabeth Forminard Executive VP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
2,555
+28.51%
|
-
|
|
Feb 13
2023
|
Robert J Decker VP Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
397
-2.29%
|
$64,314
$162.01 P/Share
|
|
Feb 13
2023
|
Robert J Decker VP Corporate Controller |
BUY
Grant, award, or other acquisition
|
Direct |
1,451
+7.73%
|
-
|
|
Feb 13
2023
|
Joaquin Duato CEO and Chairman of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
13,599
-4.12%
|
$2,203,038
$162.01 P/Share
|